公开(公告)号：WO2016032882A1

公开(公告)日：2016-03-03

申请号：PCT/US2015/046238

申请日：2015-08-21

Applicant: STC.UNM

Inventor： BESWICK, Ellen, Janine ,  MORRIS, Katherine, Theresa

IPC: A61K31/167 ,  A61K31/5517 ,  A61K31/437 ,  A61K31/47 ,  A61K31/497 ,  A61K31/4995 ,  A61P35/00

CPC classification number: A61K31/167 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/551 ,  A61K31/553 ,  A61K38/005 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.

Abstract translation: 本发明涉及MK2在癌组织中高度表达的发现，并且使用MK2抑制剂抑制MK2代表治疗癌症的可行方法，包括耐药性癌症，转移性癌症和复发性癌症。 本文所述的MK2抑制剂可以单独使用或与至少一种另外的抗癌剂组合用于治疗癌症。